Medicenna Therapeutics Corp
MDNA
Company Profile
Business description
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Contact
2 Bloor Street West
Suite 903
TorontoONM4W 3E2
CANT: +1 416 964-5442
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
17
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.70 | 38.20 | 0.43% |
| CAC 40 | 8,135.03 | 35.06 | -0.43% |
| DAX 40 | 23,730.66 | 145.89 | -0.61% |
| Dow JONES (US) | 47,147.48 | 309.74 | -0.65% |
| FTSE 100 | 9,679.23 | 19.14 | -0.20% |
| HKSE | 26,384.28 | 188.18 | -0.71% |
| NASDAQ | 22,900.59 | 30.23 | 0.13% |
| Nikkei 225 | 50,323.91 | 52.62 | -0.10% |
| NZX 50 Index | 13,499.04 | 34.58 | 0.26% |
| S&P 500 | 6,734.11 | 3.38 | -0.05% |
| S&P/ASX 200 | 8,636.40 | 32.30 | 0.38% |
| SSE Composite Index | 3,972.03 | 18.46 | -0.46% |